Sharemaestro Newsreel

Is Sanofi (ENXTPA:SAN) Cheap Following MenQuadfi Approval For Infants?

Sanofi received European Commission approval to expand the MenQuadfi meningococcal vaccine's use to infants as young as six weeks old, covering a high-risk population. Despite this and a recent share buyback, Sanofi's stock performance has been subdued. The company's valuation narrative suggests it is …

Biotechnology Stocks To Watch As Investors Look Past Pfizer’s Covid Revenue Drop

Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution …

Novo Nordisk A/S Q2 Earnings Call Highlights

Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower …

MIRA Pharmaceuticals Reports Positive Toxicokinetic Data For SKNY-1 In Obesity

(RTTNews) - MIRA Pharmaceuticals Inc. (MIRA), a clinical-stage pharmaceutical company, on Thursday reported positive toxicokinetic data for SKNY-1 to facilitate future studies as a GLP-1 drug with potential for treating obesity. SKNY-1 has shown dose-dependent reductions in body weight alongside lean body mass preservation …

When Leverage Goes Wrong on Wall Street

In this episode of Motley Fool Hidden Gems Investing, Motley Fool contributors Travis Hoium and Lou Whiteman, along with Motley Fool analyst Jason Moser, discuss: Situational Awareness.Leverage gone wrong.Hyperscaler divergence.Would you rather?Tesla in China.Stocks on our radar. To catch full episodes of all The …

How Much Do You Need Invested to Out-Earn the Average Social Security Check With Dividends?

Quick Read Replacing the $24,000 average Social Security check with dividends requires $685,000 at a 3.5% yield, $400,000 at 6%, or $240,000 at a risky 10%. A 3.5% yield growing 8% annually doubles income in 9 years, while a flat 10% yield stagnates and …

LLY Q2 Deep Dive: Key Products and Pipeline Expansion

Global pharmaceutical company Eli Lilly (NYSE:LLY)reported Q2 CY2026 results topping the market's revenue expectations , with sales up 47.7% year on year to $22.97 billion. The company's full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts' estimates. Its non-GAAP …

Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?

Key Points Medtronic has launched new devices that will help further improve its financial results. Intuitive Surgical's latest da Vinci system could expand its addressable market. Each stock will appeal to investors with different priorities. 10 stocks we like better than Medtronic › Medtronic(NYSE: …

Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with …

Jim Cramer Is Telling Investors to Accumulate SpaceX for the Long Term

During CNBC's Mad Money episode aired on August 5, Jim Cramer addressed investor concerns surrounding Space Exploration Technologies Corp. (NASDAQ:SPCX) and its immense capital requirements. Explaining why he remains bullish on SpaceX's long-term trajectory despite the massive expenditures involved, Cramer stated: I want to …

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Key Points Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising. One of these stocks looks far more attractive than the other. 10 stocks we like better than Eli …

SA Asks: What's the outlook for Big Pharma M&A?

[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a …

Pfizer $44M settlement: How to know if you are included

Pfizer will pay $44 million to settle a class-action lawsuit concerning its smoking-cessation drug Chantix, which allegedly contained an undisclosed nitrosamine. The settlement covers U.S. individuals and third-party payors who purchased Chantix between September 29, 2015, and September 17, 2021. Claimants must file by …

Biogen Inc. (BIIB) Options Chain

This article provides the options chain data for Biogen Inc. (BIIB), including calls and puts that are in the money for the August 28, 2026 expiry. It lists detailed information such as strike prices, last trade dates, last prices, bid/ask spreads, volume, open interest, …

Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets

[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from …

Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech

Key Points Intuitive Surgical makes the da Vinci surgical robot, with 11,710 systems in use globally. Medical device competitors Medtronic and Johnson & Johnson are bringing out their own surgical robots. Intuitive Surgical's largest revenue source isn't the sale of new da Vinci systems.10 …

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

Key Points iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total return of 80.2% but a significantly …

Why PG, JNJ, and KO Could Surprise Investors Next Year

Quick Read PG and JNJ target $180 and $300 respectively, with JNJ's oncology pipeline posting drug growth up to 83% in Q1. KO's FIFA World Cup 2026 activation across 180+ markets, paired with Zero Sugar volume up 16%, builds the case for $100. It …

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

Key Points Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of …

Amgen Inc. Stock 12‑Month Price Target Raised to $378.67, Implies 6% Downside

Amgen Inc.'s average stock price target has been raised to $378.67 by 27 analysts, up from $376.44. This updated target implies a 6% potential downside based on the August 6 closing price. Despite the potential downside, the consensus rating from 35 analysts remains at …

BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped …

Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week

Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] …

AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical …

Insider trades: Microsoft, Meta, Pfizer among notable names

[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small …

Insider trades: Microsoft, Meta, Pfizer among notable names (PFE:NYSE)

This article reports on notable insider trading activity that occurred between August 3 and August 7, 2026, involving several major companies. Executives at Microsoft and Meta divested portions of their holdings, while insider purchases were observed in companies like Pfizer, Taiwan Semiconductor, and Tilray …

Pfizer, Inc. (PFE) Stock Forecasts

Argus Senior Analyst David H. Toung has published a report on Pfizer Inc. (PFE), highlighting strong growth from the company's non-COVID products. The report provides a summary of Pfizer's position as a leading developer of pharmaceuticals and biotech drugs, including oncology, immunology, rare disease …

Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion

Eli Lilly delivered a strong Q2 2026, with revenues increasing by 48% due to high demand for MOUNJARO and ZEPBOUND. The company maintains a "Strong Buy" rating based on double-digit growth in key drugs and successful pipeline developments, including positive phase 3 data for …

Key HIV stat over 70% leaves BofA siding with Gilead

Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was …

Organon & Co. (OGN) Stock Forecasts

This article provides a brief overview of Organon & Co. (OGN), a pharmaceutical company focused on women's health, biosimilars, and established brands. It references an Argus research report from August 5, 2026, which includes a summary of the company and its current stock price …

Eli Lilly and Company Just Beat Revenue By 11%: Here's What Analysts Think Will Happen Next

Eli Lilly and Company reported strong quarterly results, with revenues beating analyst forecasts by 11% and EPS exceeding expectations by 5.3%. Following these results, analysts have modestly increased their revenue and earnings per share predictions for 2026, though the consensus price target of US$1,301 …

Earnings Scoreboard: 86% of S&P 500 reporting firms top EPS estimates as 79% post Y/Y profit growth

[Rolled newspaper with the headline Quarterly Results] Zerbor S&P 500 earnings activity accelerated this week, with more than 130 index members reporting quarterly results that provided key insights into corporate margin health, spending trends, and overall macroeconomic strength. EARNINGS ROUNDUP: * BOTTOM LINE (EPS): …

Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed?

Amgen's stock rose 6.7% after the European Medicines Agency's CHMP supported broader use of its drug Repatha for high-risk atherosclerotic cardiovascular disease patients in Europe. This potential expansion, driven by positive Phase 3 trial data, could significantly increase Repatha's eligible patient base. While strengthening …

Organon & Co (OGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Merck & Co., Inc. $MRK Shares Sold by Rockland Trust Co.

Rockland Trust Co. reduced its stake in Merck & Co., Inc. by 8.4% in the second quarter, selling 44,914 shares while still holding 490,049 shares valued at $63 million. Despite this, other institutional investors increased their positions, and institutions collectively own 76.07% of the …

Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed

In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …